Balyasny Asset Management LLC Aurinia Pharmaceuticals Inc. Transaction History

Balyasny Asset Management LLC

$54.8 Billion
Q1 2024

A detailed history of Balyasny Asset Management LLC transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 288,875 shares of AUPH stock, worth $1.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

288,875

Previous 887,014 67.43%

Holding current value

$1.65 Million

Previous $7.97 Million 81.85%

% of portfolio

0.0%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$4.93 - $9.31 $2.95 Million - $5.57 Million	-598,139 Reduced 67.43%	288,875 $1.45 Million
Q4 2023 Feb 14, 2024	BUY	$7.13 - $9.49 $4.45 Million - $5.92 Million	624,186 Added 237.49%	887,014 $7.97 Million
Q3 2023 Nov 14, 2023	SELL	$7.77 - $12.27 $4.22 Million - $6.66 Million	-542,706 Reduced 67.37%	262,828 $2.04 Million
Q2 2023 Aug 14, 2023	SELL	$8.96 - $11.69 $4.54 Million - $5.92 Million	-506,813 Reduced 38.62%	805,534 $7.8 Million
Q1 2023 May 15, 2023	BUY	$5.94 - $11.27 $5.06 Million - $9.61 Million	852,516 Added 185.4%	1,312,347 $14.4 Million

Q4 2022 Feb 14, 2023	SELL	$4.11 - $8.14 $1.62 Million - $3.21 Million	-393,956 Reduced 46.14%	459,831 $1.99 Million
Q3 2022 Nov 14, 2022	BUY	$6.66 - $12.39 $2.36 Million - $4.39 Million	354,536 Added 71.01%	853,787 $6.42 Million
Q2 2022 Aug 15, 2022	SELL	$8.95 - $12.8 $387,991 - $554,892	-43,351 Reduced 7.99%	499,251 $5.02 Million
Q1 2022 May 16, 2022	BUY	$10.05 - $22.48 $5.45 Million - $12.2 Million	542,602 New	542,602 $6.72 Million
Q1 2018 May 15, 2018	SELL	$4.85 - $5.99 $2.43 Million - $3 Million	-500,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.71 - $6.9 $2.86 Million - $3.45 Million	500,000	500,000 $3.14 Million

Others Institutions Holding AUPH

# of Institutions

205

Shares Held

55.6M

Call Options Held

838K

Put Options Held

1.18M

View Full List

About Aurinia Pharmaceuticals Inc.

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $810M
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

More about AUPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Account

Balyasny Asset Management LLC Aurinia Pharmaceuticals Inc. Transaction History